Publications

  1. Keller ET. Elevated trypsin-like immunoreactivity in a dog with exocrine pancreatic insufficiency and chronic pancreatitis. J Am Vet Med Assoc;196:623-626, 1990.
  2. Keller ET. Testing for exocrine pancreatic insufficiency in cats. (Letter). J Am Vet Med Assoc 197:1112-1114, 1990.
  3. Keller ET, Madewell BR. Locations and types of neoplasms in immature dogs: 69 cases (1964-1989). J Am Vet Med Assoc 200:1530-1532, 1992.
  4. Keller ET, Vail DM. Intrapleural cisplatin as a cause of paroxysmal ventricular tachycardia. (Letter). J Vet Int Med 6:198-199, 1992.
  5. Keller ET. Immune-mediated disease as a risk factor for canine lymphoma. Cancer 70:2334-2337, 1992.
  6. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Int Med. 7:289-295, 1993.
  7. Keller ET. Gene therapy for the dog. Veterinary Cancer Society Newsletter. 18(1), 10-11, 1994.
  8. MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox
  9. LE, Keller ET, Obradovich J, Madewell B, Rodriguez C, Kitchell B, Fidel J, Susaneck S, Rosenberg M. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Targeting. 2:391-3966, 1994.
  10. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide in vitro proliferation of myeloma cells. J Immunol. 154:4091-4098, 1995.
  11. Kisseberth WC, MacEwen EG, Helfand SC, Vail DM, London CL, Keller ET. Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. J Vet Int Med. 9:425-428, 1995.
  12. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, Obradovich J, Fidel J, Rosenberg M. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1:1595-1601, 1995.
  13. Padgett GA , Madewell BR, Keller ET, Jodar L, Packard M. Inheritance of histiocytosis in Bernese mountain dogs. J Small Animal Practice. 36:93-98, 1995.
  14. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee H, Wang C, Mizokami A. Androgen receptor: An overview. Crit Rev Euk Gene Trans. 5:97-125, 1995.
  15. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Frontiers in Bioscience 1:59-69, 1996.
  16. Keller ET, Chang C, Ershler WB. Inhibition of NFkB through maintenance of IkB levels contributes to dihydrotestosterone-mediated inhibition of the interleukin-6 promoter. J Biol Chem, 271:26267-26275, 1996.
  17. Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, MacEwen EG, Malter JS, Yang NS, Ershler WB. In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. Cancer Gene Therapy 3:186-191, 1996.
  18. Keller ET, Wanagat, J, Ershler, WB. The molecular and cellular biology of interleukin-6 and the interleukin-6 receptor. Frontiers in Bioscience, 1:340-357, 1996. (http://www.bioscience.org/ 1996/v1/d/keller2/htmls/340-357.htm)
  19. Keller ET, Pugh TD, Sun WH, Ershler WB. Evaluation of ovariectomy and dehydro-epiandrosterone sulfate administration on interleukin-6 levels and B16 melanoma growth in mice. Age, 19:75-81, 1996.
  20. Martinez E, Moore DD, Keller ET, Pearce D, Robinson V, Simons Jr, S, Sanchez E, Danielsen M. The Nuclear Receptor Resource Project. Nucl Acids Res, 25:163-165, 1997.
  21. Keller ET. Of Mice and Women, Trends Endocrinol Metab, 8:327-328, 1997.
  22. Keller ET, Zhang J, Ershler WB. Ethanol activates the interleukin-6 promoter in a human bone marrow stromal cell line. J Gerontol: Biol Sci 52A:B311-317, 1997.
  23. Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Develop Compar Immunol 21:487-499, 1997.
  24. Martinez E, Moore DD, Keller ET, Pearce D, Vanden Huevel JP, Robinson V, Simons Jr, Gottlieb B, MacDonald P, Simons Jr, S, Sanchez E, Danielsen M. The nuclear receptor resource: a growing family. Nucl Acids Res 26:239-241, 1998.
  25. Zhang J, Pugh TD, Stebler, B, Ershler WB, Keller ET. Orchiectomy increases bone-marrow interleukin-6 levels in mice. Calcif Tiss Int 62:219-226, 1998.
  26. Sun WH, Keller ET, Stebler BS, Ershler WB. Estrogen inhibits phorbol ester-induced I k B transcription and protein degradation. Biophys Biochem Res Com, 244:691-695, 1998.
  27. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang N-S, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor transfected tumor cell vaccines for the treatment of spontaneous canine canc er. Human Gene Therapy, 9:1851-1861, 1998.
  28. Binkley N, Ellison G, O'Rourke C, Hall D, Johnston G, Kimmel D, Keller ET. A rib biopsy technique for the cortical bone evaluation in rhesus monkeys (Macaca mulatta). Lab Animal Sci, 49:87-89, 1999.
  29. Keller ET, Gravenstein SG. The Biology of Aging: Genetic and Immunologic Influences. In “Towards a Healthier Old Age”, Prous Science Telesymposium, , 1999.
  30. Chiu KM, Kiami PH, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydroepiandrosterone sulfate (DHEAS) levels with age and gender in healthy adult people. Age Ageing, 28:211-216, 1999.
  31. Chiu KM, Keller ET, Crenshaw TD, Gravenstein S. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcif Tissue Int. 64:527-533, 1999.
  32. Keller ET, Binkley NC, Stebler BA, Hall DM, Johnston G, Zhang J, Ershler WB. Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (Maccaca mulatta). Bone. 26:55-62, 2000.
  33. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S, Keller ET. Correlation of estradiol, parathyroid hormone, interleukin-6 and interleukin-6 receptor during the normal menstrual cycle. Bone. 26:79-85, 2000.
  34. Knezevic-Cuca J, Stansberry KB, Johnston G, Zhang J, Keller ET, Vinik AI, Pittenger GL. Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. J Neuroimmunol. 102:8-16, 2000.
  35. Ershler WB, Keller ET. Age-associated increased IL-6 gene expression, late life diseases and frailty. Ann Rev Medicine. 51:245-270, 2000.
  36. Muenchen H, Lin DL, Walsh MA, Keller ET, Pienta KJ. TNF-induced apoptosis in prostate cancer cells through inhibition of NF- k B by an I k B a “Super-Repressor.” Clin Cancer Res. 6:1969-1977, 2000.
  37. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor- represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol. 164:800-805, 2000.
  38. Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through interleukin-6 in mice. J Clin Invest. 106:887-895, 2000.
  39. Morris MD, Tarnowski CP, Timlin A, Carden A, Dreier JL, Ignelzi MA Jr., Lin DL, Keller ET. Raman imaging as a probe of chemical and biomechanical properties of bone tissue. Proc. SPIE, 3918, 151-158, 2000.
  40. Smith PC, Hobish A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine and Growth Factor Rev. 12:33-40, 2001.
  41. Keller ET, Zhang J, Yao Z, Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause. J Repro Immunol. 50:41-55, 2001.
  42. Yao Z, Zhang J, Dai, J, Keller ET. Ethanol activates NF k B DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. Bone, 28:167-173, 2001.
  43. Lin DL, Tarnowski CP, Patel AH, Rohn E, Morris MD, Keller ET. The bone metastatic LNCaP-derivative C4-2B prostate cancer cell line induces mineralization in vitro. Prostate, 47:212-221, 2001.
  44. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Longterm exposure of tumor necrosis factor- a causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate, 46:319-326, 2001.
  45. Zhang J, Dai J Smith P, Qi Y, Lin D, Strayhorn C, Mizokami A, Fu Z, and Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone of mice. J Clin Invest, 107:1235-1244, 2001.
  46. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NF k B-inducing kinase activity. Antioxidant Redox Signaling, 3:493-504, 2001.
  47. Richard V, Lairmore MD, Green PL, Feuer G, Erbe RS, Albrecht B, Keller ET, Dai J, Rosol TJ. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am J Pathology, 158:2219-2228, 2001.
  48. Smith PC and Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate, 48:47-53, 2001.
  49. Lin DL, M Whitney, Z Yao, Keller ET. Interleukin-6 induces androgen receptor activity through up-regulation of receptor expression in prostate cancer cells. Clin Cancer Res, 7:1773-1781, 2001.
  50. Evan T. Keller, Jian Zhang, Carlton R. Cooper, Peter C. Smith, Laurie K. McCauley, Kenneth J. Pienta and Russell S. Taichman. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Reviews 20:333-349, 2001.
  51. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells similar to that found in bone metastatic prostate cancer cells. Prostate, 51:10-20, 2002.
  52. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today, 38:91-102, 2002.
  53. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 62: 1832-1837, 2002.
  54. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Min Res 17:1256-1263, 2002.
  55. Demiralp, B., H. Chen, A.J. Koh-Paige, E.T. Keller, and L.K. McCauley. Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos. Endocrinology 143:4028-4047, 2002.
  56. Stewart S, Shea DA, Tarnowski CP, Morris MD, D Wang Franceschi R, Lin DL and E Keller, Trends in early mineralization of murine calvarial osteoblastic cultures. A Raman microscopic study. Journal of Raman Spectroscopy. 33: 536-543, 2002.
  57. Keller ET. Overview of metastasis and metastases. Journal of Musuloskeletal Neuronal Interactions. 2:567-569, 2002.
  58. Keller ET, Yao Z. Applications of high-throughput methods to cancer metastases. Journal of Musuloskeletal Neuronal Interactions. 2:575-578, 2002.
  59. Fujita H, Koshida K, Keller ET, Takahasi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53:232-240, 2002.
  60. Khorram O, Colman RJ, Kemnitz JW, Magness RR, Zhang J, Yao Z, Keller ET. The influence of sex hormones on circulating nitric oxide (NOx) levels in Rhesus monkeys (Macaca mulatta). Med Sci Monit 8:BR489-95, 2002.
  61. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Stromal factors involved in prostate carcinoma metastasis to the bone. Cancer (suppl) 97:739-747, 2003.
  62. Keller ET and J. Brown JM. Osteoprotegerin (OPG), receptor activator of NF k B ligand (RANKL) and RANK in cancer metastasis. Research Advances in Cancer 3:81-93, 2003.
  63. McCauley LK, Tozum TF, Kozloff KM, Koh-Paige AJ, Chen C, Demashkieh M, Cronovixh H, Richard V, Keller ET, Rosol TJ, Goldstein SA. Transgenic models of metabolic bone disease: Impact of estrogen receptor deficiency on skeletal metabolism. Connect Tissue Res 44(Suppl. 1):250-263, 2003.
  64. Murtha JM, Qi W, Keller ET.. Hematologic and serum biochemical values for zebrafish (Danio rerio). Comp Med 53:37-41, 2003.
  65. Murtha JM, Qi W, Keller ET. Characterization of the Heat Shock Response in Mature Zebrafish (Danio rerio). Experimental Gerontol. 38:683-691, 2003.
  66. Fu Z, Smith PC, Zhang L, Rubin M, Dunn RL, Yao Z, Keller ET. Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis. J Natl Cancer Inst.95:878-889, 2003. Has accompanying editorial.
  67. Varani J, Fligiel H, Zhang J, Aslam MN, Lu Y, Dehne LA, Keller ET. Separation of retinoid-induced epidermal thickening from skin irritation. Arch Dermatol Res. 295:255-262, 2003.
  68. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Min Res. 18:1882-1888, 2003.
  69. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate cancer progression in bone. Cancer Res. 63:7883-7890, 2003.
  70. Kacergius T, Deng Y, Keller ET. Influenza virus and gamma interferon synergistically increase nitric oxide production in RAW 264.7 and AMJ2-C11 macrophages. Acta Medica Lituanica 10:174-184, 2003.
  71. Lester PR, Keller ET. The comparative biology of skeletal metastasis. Vet Comp Oncol. 1:131-139, 2003.
  72. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 64:994-999, 2004.
  73. Keller ET, Brown J. Prostate cancer bo ne metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 91:718-729, 2004.
  74. Zhang J, Lu Y, O’brien CA, Dai J, Qi W, Hall DE, Manolagas SC, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: Evidence for free radical theory of aging. Experimental Gerontology.39:239-247, 2004.
  75. Artz AS, Fergusson D, Drinka PJ, Gerald M, Bidenbender R, Lechich A, Silverstone F, McCamish MA, Dai J, Keller E and Ershler WB, Mechanisms of Unexplained Anemia in the Nursing Home. J Am Geriatr Soc 52:423-427, 2004.
  76. Keller ET, Fu Z. Defining RKIP as a protein that regulates prostate cancer metastasis. Am J Urolog Rev 2:72-80, 2004. Accompanying commentary on pp 81-83.
  77. Keller ET. Signal transduction pathways as therapeutic targets. IDrugs 7:217-222, 2004.
  78. Zhang J, Lu Y, Dai J, Yao Z, Kitazawa R, Kitazawa S, Zhao X, Hall DE, Pienta KJ, Keller ET. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate 2004;59(4):360-369.
  79. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagawa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-17523, 2004.
  80. Keller, ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: A prostate cancer metastasis suppressor gene. Cancer Letters 207:131-137, 2004.
  81. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771, 2004.
  82. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone JF, Aguzzi A, Ershler WB, Dai J, Fraser P, Hysloop PSG, Holtzman DM, Walker LC, Keller ET. Alzheimer Aß Vaccination of Rhesus Monkeys (Macaca mulatta) Mech Ageing Dev 125:149-151, 2004.
  83. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D’Silva NJ, McCauley LK. Impact of Mitogen-activated Protein Kinase (MAPK) Pathway on Parathyroid Hormone Related Protein Actions in Osteoblasts. J Biol Chem 279:29121-29129, 2004.
  84. Loberg RD, Fridman Y, Pienta B, Keller E T, McCauley L, Taichman R, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancer: A review. Neoplasia 6(4):302-9, 2004.
  85. Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68(6):1049-53, 2004.
  86. Keller ET. Metastasis suppressor genes: A role for raf kinase inhibitor protein (RKIP). Anti-cancer drugs 15(7):663-9, 2004.
  87. Gerhard GS, Malek RL, Cheng KC, Keller ET, Murtha J. Zebrafish, killifish, neither fish, both fish? (Letter) J Exp Gerontol 59(9):B873-B875, 2004.
  88. Keller ET, Murtha JM. The use of mature zebrafish (Danio rerio) as a model for human aging and disease Compar Biochem Physiol 138(3): 335-341, 2004.
  89. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21(5):381-387.
  90. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004;21(5):399-408.
  91. Keller ET, Hall C, Dai J, Wallner L. Biomarkers of growth, differentiation, and metastasis of prostate epithelium. J Clin Lig Assay 27(2) 133-136, 2004
  92. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94(2): 273-278, 2005.
  93. Sun Y, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman N, Liang Z, Koh-Paige A, Shim H, Pienta K, Keller E, McCauley L, and Taichman RS. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Min Res 20(2): 318-329, 2005.
  94. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146(4):1727-1736.
  95. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005.
  96. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn RL, Chinnaiyan AM, Yao Z, Keller ET. The metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, In Press.
  97. Hall CL, Bafico A, Dai J, Aaronson SA, and Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Priority Report. Cancer Res, In Press.
  98. Dai J, Keller JM, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res, In Press.
  99. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer. Cancer Res, In Press.
  100. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. The pathogenesis and treatment of prostate cancer bone metastases. J Clin Oncol, In Press.
University of Michigan Medical School Urology Department
html> ml> html> ceEnd -->